Prot #CA209-703: NU MRFBC 16M05: A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed

Project: Research project

Project Details

StatusFinished
Effective start/end date9/15/17 → 7/14/20

Funding

  • Georgetown University (Prot #CA209-703 // Prot #CA209-703)
  • Bristol-Myers Squibb Company (Prot #CA209-703 // Prot #CA209-703)